Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trialin bipolar depression Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for theadjunctive treatment of major depressive disorder (MDD) in early 2027 Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025, and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029 NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of MDD, and other neuropsychiatric diseases, today announced financial results for the fourth quarter and full year ended on December 31, 2025 and provided a corporate update. “2025 was a transformative year for LB.
